Posts Tagged ‘Novartis’

At any given time, a principal investigator (PI) can be working on one or more studies for a single sponsor company, or multiple studies for multiple sponsors. Likewise, each sponsor runs its clinical trials its own way, using its preferred technology and processes. And, often times, the technology and/or processes differ from study to study, […]

Now that November is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in October – they’re ranked in order of popularity, with number one being the most viewed piece. Aggregate Report Preparation In Safety […]

On September 4, 2017, Novartis announced that its current CEO, Joseph Jimenez, will step down from his role in February 2018. He will be replaced by Dr. Vasant Narasimhan, the company’s current global head of drug development and chief medical officer. The backgrounds of the two executives couldn’t be starker. Mr. Jiminez has very little […]

Last year’s presidential election invoked a great deal of angst in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While the things candidates said they would do could very well be different from what they might actually do, their words and records were enough […]

In a recent post, I took an in-depth look at the first of three critical themes for success in the digital age, as identified by McKinsey & Company through interviews with 20 pharma executives: